[Preparation and characterization of potential antineoplastic agents]. 1999

L Orfi, and F Wáczek, and M Szabó, and I Kövesdi, and G Mészáros, and M Idei, and A Horváth, and F Hollósy, and M Mák, and Z Szegedi, and B Szende, and G Kéri, and B Noszál
Semmelweis Orvostudományi Egyetem, Gyógyszerészi Kémiai Intézet, Budapest.

A parallel combinatorial library of over sixteen hundred compounds has been designed and synthesized for the development of new potential peptidomimetic protein tyrosine kinase (PTK) inhibitor leads that is aimed for intervening with the substrate binding site of the pp60c-src enzyme. The new structures were based on known PTK inhibitors having at least two variously substituted aromatic moieties attached by spacer groups of different length and flexibility. Eleven bis-aryl type inhibitory compounds were found in the range of 18-100 micromolar IC50 concentrations from combinations of twelve different substituents. Molecular modeling of the active compounds showed a characteristic distance of 13-14 A between the farthest sp2 carbon atoms of the two aromatic rings. Conformational analysis of several peptide substrates recently found for pp60c-src PTK [5,6,7] showed that the energy minimized conformers had the same distance between two aromatic moieties. Several compounds in the library not only showed remarkable PTK inhibitory activity but also a significant apoptosis inducing effect on HT-29 human colon tumor cells.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

L Orfi, and F Wáczek, and M Szabó, and I Kövesdi, and G Mészáros, and M Idei, and A Horváth, and F Hollósy, and M Mák, and Z Szegedi, and B Szende, and G Kéri, and B Noszál
January 2006, Annales pharmaceutiques francaises,
L Orfi, and F Wáczek, and M Szabó, and I Kövesdi, and G Mészáros, and M Idei, and A Horváth, and F Hollósy, and M Mák, and Z Szegedi, and B Szende, and G Kéri, and B Noszál
June 1964, Journal of pharmaceutical sciences,
L Orfi, and F Wáczek, and M Szabó, and I Kövesdi, and G Mészáros, and M Idei, and A Horváth, and F Hollósy, and M Mák, and Z Szegedi, and B Szende, and G Kéri, and B Noszál
April 1983, The Medical journal of Australia,
L Orfi, and F Wáczek, and M Szabó, and I Kövesdi, and G Mészáros, and M Idei, and A Horváth, and F Hollósy, and M Mák, and Z Szegedi, and B Szende, and G Kéri, and B Noszál
March 1964, Journal of medicinal chemistry,
L Orfi, and F Wáczek, and M Szabó, and I Kövesdi, and G Mészáros, and M Idei, and A Horváth, and F Hollósy, and M Mák, and Z Szegedi, and B Szende, and G Kéri, and B Noszál
August 1984, Bollettino chimico farmaceutico,
L Orfi, and F Wáczek, and M Szabó, and I Kövesdi, and G Mészáros, and M Idei, and A Horváth, and F Hollósy, and M Mák, and Z Szegedi, and B Szende, and G Kéri, and B Noszál
August 2001, Trends in immunology,
L Orfi, and F Wáczek, and M Szabó, and I Kövesdi, and G Mészáros, and M Idei, and A Horváth, and F Hollósy, and M Mák, and Z Szegedi, and B Szende, and G Kéri, and B Noszál
March 1969, Journal of medicinal chemistry,
L Orfi, and F Wáczek, and M Szabó, and I Kövesdi, and G Mészáros, and M Idei, and A Horváth, and F Hollósy, and M Mák, and Z Szegedi, and B Szende, and G Kéri, and B Noszál
March 1963, Journal of medicinal chemistry,
L Orfi, and F Wáczek, and M Szabó, and I Kövesdi, and G Mészáros, and M Idei, and A Horváth, and F Hollósy, and M Mák, and Z Szegedi, and B Szende, and G Kéri, and B Noszál
November 1964, Journal of pharmaceutical sciences,
L Orfi, and F Wáczek, and M Szabó, and I Kövesdi, and G Mészáros, and M Idei, and A Horváth, and F Hollósy, and M Mák, and Z Szegedi, and B Szende, and G Kéri, and B Noszál
September 2003, Mini reviews in medicinal chemistry,
Copied contents to your clipboard!